Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8377420 | 0.77 | RAB9A (0.51) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4140149 | 0.77 | RAB9A (0.48) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL28801723 | 0.77 | RAB9A (0.51) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL12689025 | 0.77 | KDM4E (0.48) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL12051092 | 0.77 | THRB (0.51) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL17788473 | 0.77 | RAB9A (0.55) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL15001259 | 0.75 | RAB9A (0.65) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL9564367 | 0.74 | RAB9A (0.52) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL19668537 | 0.73 | NOTUM (0.57) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL619636 | 0.73 | RAB9A (0.62) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| EP-2721034-B1 | N-HETEROTRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9321788-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9321788-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-7531548-B2 | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2009-05-12 | — | — | US | disclosed |
| US-7531548-B2 | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines | TIBOTEC PHARMACEUTICALS LTD (IE) | 2009-05-12 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| US-20070208022-A1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLYL SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-09-06 | — | — | US | disclosed |
| US-20070208022-A1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLYL SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-09-06 | — | — | US | disclosed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | RAB9A 1564/4885SMN1; SMN2 1740/4885MEN1 3817/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | RAB9A 2968/4885SMN1; SMN2 4383/4885MEN1 1840/4885 |
| US-20070208022-A1 | HIV INHIBITING 5-CARBO- OR HETEROCYCLYL SUBSTITUTED PYRIMIDINES | CCNO, COX6C, CCR6 | RAB9A 2174/4885SMN1; SMN2 4275/4885MEN1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.